Skip to main content

BIO

Stock

BIO

Stock
Health Care
Medical Devices

Performance overview

BIO Price
Price Chart

Forward-looking statistics

Beta
0.82
Risk
36.30%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Bio-Rad Laboratories Inc manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. It operates in two industry segments; In Clinical Diagnostics segment, the company manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In Life Sciences segment, the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with majority of the revenue being generated from United States, it also has its presence in Europe, Asia, Canada and other regions.

Company info

SectorHealth Care
IndustryMedical Devices
Employees8K
Market cap$8.2B

Fundamentals

Enterprise value$6.3B
Revenue$2.5B
Revenue per employee—
Profit margin-85.16%
Debt to equity20.50

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$76.52
Dividend per share—
Revenue per share$90.53
Avg trading volume (30 day)$104M
Avg trading volume (10 day)$102M
Put-call ratio—

Macro factor sensitivity

Growth-0.4
Credit+3.9
Liquidity+0.4
Inflation-4.0
Commodities+0.2
Interest Rates-1.7

Valuation

Dividend yield0.00%
PEG Ratio21.59
Price to sales2.66
P/E Ratio21.59
Enterprise Value to Revenue2.47
Price to book1.04

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day—
Ex. dividend day—

News

New Strong Sell Stocks for July 10th

BIO, DECK and ELUXY have been added to the Zacks Rank #5 (Strong Sell) List on July 10, 2025.

Zacks Investment Research (July 10, 2025)
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

Zacks Investment Research (July 8, 2025)
It is time for a move higher in biotech, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.

CNBC Television (July 7, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free